Australia markets closed

(SVQ.BE)

Berlin - Berlin Delayed price. Currency in USD
Add to watchlist
5.590.00 (0.00%)
At close: 08:08AM CET
Full screen
Previous closeN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's rangeN/A - N/A
52-week range5.59 - 5.59
VolumeN/A
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Sinovac Amends Shareholder Rights Plan

    BEIJING, February 21, 2024--Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

  • Business Wire

    Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

    BEIJING, January 18, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT

  • Business Wire

    SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

    BEIJING, September 11, 2023--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.